Insulet Corporation · NASDAQ:PODD
Insulet — Q3 2026 Earnings Presentation
16 slides from Insulet's earnings presentation, Nov 4, 2026
Slide 1: Q3 2026 earnings
Q3 2026 earnings Erick November 4, 2026 Podder with T2 since 2025
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements regarding, among other things, failure to retain key suppliers; challenges to the future development of our non-insulin future operating and financial performance, product success and efficacy, the outcome drug delivery prod
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company uses the following non-GAAP financial measures: • Constant currency revenue growth, which represents the change in revenue Insulet presents these non-GAAP financial measures because management uses them between current and prior-year periods using the exchange
Slide 4: Q3 2026 performance
Q3 2026 performance Total revenue Omnipod revenue by geography Other financial highlights ADJUSTED OPERATING MARGIN1 U.S. Omnipod $570.4M 22.0% 14.7% Total Company Total Omnipod up 490 bps $842.0M $836.6M ADJUSTED EARNINGS PER SHARE1 19.2%, 19.7%, 19.6% constant currency1 20.0% constant currency1 In
Slide 5: Progress against our strategic objectives
Progress against our strategic objectives Advanced commercial objectives, executing T2 action plan to strengthen onboarding, support, sampling, and aligning sales incentives with NCS and retention goals Completed full U.S. market release of Omnipod Discover®, driving adoption by more than 35,000 use
Slide 6: In Q3 We: Key commercial metrics
Key commercial metrics5 Completed U.S. sales force expansion, adding ~25% more field coverage U.S. field reps completed new four-month upskilling program In Q3 Grew the U.S. prescriber base to nearly 34,000 HCPs prescribing Omnipod +20% #1 Brand requested by PWD and #1 brand prescribed by Endos & HC
Slide 7: FY 2026 guidance
FY 2026 guidance6 Revenue guidance7 P&L guidance Assumptions & drivers Global Omnipod growth assumes continued FY 2026 FY 2026 adjusted FY 2026 adjusted Omnipod 5 adoption and YoY NCS growth revenue operating margin8 EPS growth8 U.S. growth assumes customer base expansion, with stable pricing, utili
Slide 8: Thank you
Thank you Insulet
Slide 9: Appendix
Appendix Insulet
Slide 10: Insulet common abbreviations and acronyms
Insulet common abbreviations and acronyms A1C Blood test measures average blood glucose levels over the last 3 months GLP Glucagon-like peptide ADA American Diabetes Association HCP Health Care Provider AID Automated Insulin Delivery iOS iPhone Operating System ASP Average Selling Price KOL Key Opin
Slide 11: Q3 2026 financial performance
Q3 2026 financial performance $s in Millions Total Revenue9 Total Omnipod9 Adjusted Gross Profit & Margin 20% 20% 28% $842 29% 74.2% $837 72.2% $706 $699 $625 $510 10 Q3'25 Q3'26 Q3'25 Q3'26 Q3'25 Q3'26 U.S. Omnipod International Omnipod9 Adjusted Operating Income & Margin 15% 26% 33% 22.0% $570 40%
Slide 12: Historical & YTD financial performance
Historical & YTD financial performance $s in Billions Total Revenue9 Total Omnipod9 Gross Profit & Margin 30% 30% 24% 25% 71.6% $2.7 72.8% 22% $2.7 22% 30% 30% $2.4 $2.4 69.8% $1.9 71.3% $1.8 30% 33% $2.1 $2.0 67.7% 22% $1.9 27% $1.9 $1.4 $1.7 $1.7 66.2% $1.4 $1.1 $1.3 $1.2 $0.9 10 10 2022 2023 2024
Slide 13: Non-GAAP reconciliation — revenue guidance
Non-GAAP reconciliation — revenue guidance Year Ending December 31, 2026 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 17.5% to 18.5% —% 17.5% to 18.5% International Omnipod 35% to 36% 3% 32% to 33% Total Omnipod 22.5% to 23.5% 1% 21.5% to 22.5% Drug Delivery ~(40)% —% ~(40)% To
Slide 14: Reconciliations of historical non-GAAP measures
Reconciliations of historical non-GAAP measures $s in Millions Q3 2026 Q3 2025 YTD 2026 YTD 2025 2025 2024 2023 2022 Total Revenue GAAP Growth Rate 19.2 % 29.9 % 25.0 % 30.5 % 30.7 % 22.1 % 30.0 % 18.8 % Less: Currency Impact (0.4)% 1.7 % 1.2 % 0.8 % 1.2 % 0.2 % 0.4 % (3.7)% Constant Currency 19.6 %
Slide 15: Reconciliation of historical non-GAAP measures
Reconciliation of historical non-GAAP measures Q3 2026 Q3 2025 YTD 2026 YTD 2025 2025 2024 2023 2022 GAAP Diluted EPS $ 2.03 $ 1.24 $ 4.69 $ 2.05 $ 3.48 $ 5.78 $ 2.94 $ 0.07 Voluntary MDCs and related costsa (0.05) — 0.37 — — — (0.16) 0.83 Legal costsb — — — — — — — 0.36 CEO and CFO transition costs
Slide 16: Endnotes
Endnotes Page Title Marker Footnote 4,5 Q3 2026 performance, 1 Growth rates are on a YoY basis. Constant Currency, adjusted operating margin and adjusted earnings per share are Progress against our strategic objectives non-GAAP measures. See description of non-GAAP financial measures contained in th